Advances in both sensitivity and specificity of analytical chemistry have made it possible to
quantify substances in human biological specimens, such as blood, urine, and breast milk …

This review summarizes the most recent developments in and applications of physiologically
based pharmacokinetic (PBPK) modeling methodology originating from both the …

We have previously demonstrated that a small molecule inhibitor of bacterial β-
glucuronidase (Inh-1;[1-((6, 8-dimethyl-2-oxo-1, 2-dihydroquinolin-3-yl)-3-(4-ethoxyphenyl) …

Risk to human health as a consequence of toxic materials found in modern societies is a
matter of grave concern to the world community. What is more, risks to humans that arise …

Idiosyncratic drug‐induced liver injury (DILI) is a significant adverse effect of antitubercular
therapy with isoniazid (INH). Although the drug has been used for many decades, the …

Troglitazone, a first-generation thiazolidinedione antidiabetic drug, was withdrawn from the
market due to an unacceptable risk of idiosyncratic hepatotoxicity. Troglitazone does not …

Background: Whole-body physiologically-based pharmacokinetic (WB-PBPK) models
mathematically describe an organism as a closed circulatory system consisting of …

In this book, we propose original perspectives in theoretical biology. We refer extensively to
physical methods of understanding phenomena but in an untraditional manner. At times, we …

Human risk and exposure assessments require dosimetry information. Species-specific
tissue dose response will be driven by physiological and biochemical processes. While …

A physiologically-based pharmacokinetic (PBPK) model represents the structural
components of the body with physiologically relevant compartments connected via blood …